Literature DB >> 6826485

In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus.

M Foldes, R Munro, T C Sorrell, S Shanker, M Toohey.   

Abstract

Minimal inhibitory and minimal bactericidal concentrations were determined for eighteen methicillin-resistant Staphylococcus aureus isolates, the majority also resistant to gentamicin, obtained from the blood of bacteraemic patients. Fifty per cent of organisms had a greater than four-fold difference in M.I.C. and M.B.C. for vancomycin, 83% for rifampicin, and 89% for fusidic acid. In-vitro effects of two-drug combinations of vancomycin, rifampicin, and fusidic acid demonstrated neither synergy nor antagonism when measured by a checkerboard dilution technique. The relevance of these findings to choice of therapy of serious infection due to methicillin-gentamicin resistant Staph. aureus is yet to be determined.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6826485     DOI: 10.1093/jac/11.1.21

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Unique actinomycetes from marine caves and coral reef sediments provide novel PKS and NRPS biosynthetic gene clusters.

Authors:  Tyler W Hodges; Marc Slattery; Julie B Olson
Journal:  Mar Biotechnol (NY)       Date:  2011-10-15       Impact factor: 3.619

2.  Emergence and spread of rifampicin-resistant, methicillin-resistant Staphylococcus aureus during vancomycin-rifampicin combination therapy in an intensive care unit.

Authors:  O Ju; M Woolley; D Gordon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

3.  Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jason C Kwong; Kyra Chua; Patrick G P Charles
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

4.  Interaction between rifampin and fusidic acid against methicillin-resistant coagulase-positive and -negative staphylococci.

Authors:  B F Farber; Y C Yee; A W Karchmer
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

5.  Vancomycin for treatment of infections with methicillin-resistant Staphylococcus aureus: are there alternatives?

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

6.  Structure of ristocetin A in complex with a bacterial cell-wall mimetic.

Authors:  Virginie Nahoum; Sherri Spector; Patrick J Loll
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-07-17

Review 7.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  B Fantin; R Leclercq; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

9.  In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus.

Authors:  L P Elwell; H R Wilson; V B Knick; B R Keith
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

10.  Complete genome sequence and comparative genomic analyses of the vancomycin-producing Amycolatopsis orientalis.

Authors:  Li Xu; He Huang; Wei Wei; Yi Zhong; Biao Tang; Hua Yuan; Li Zhu; Weiyi Huang; Mei Ge; Shen Yang; Huajun Zheng; Weihong Jiang; Daijie Chen; Guo-Ping Zhao; Wei Zhao
Journal:  BMC Genomics       Date:  2014-05-13       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.